At a Thermo Fisher-sponsored workshop, two companies argued for the clinical utility of PGx LDTs as FDA prepared to issue a warning against unapproved tests.
Testing with Cepheid's molecular TB assay can shorten the amount of time suspected patients need to be isolated and save thousands of dollars per patient.
While a randomized-controlled trial is underway, Genomind hopes data from a new case-control study will convince insurers its PGx test can reduce healthcare utilization costs.
A new analysis says sequencing early in in the diagnostic process for infants with suspected Mendelian disorders is cost-effective.
Despite the astronomical costs, it may prove challenging to reverse course and discontinue Zika testing according to a commentary article accompanying a NEJM study.
Cases with genome and family history reports and controls with family history reports alone had comparable healthcare costs during the six months after receiving their reports.
Sentieon will integrate its DNAseq and TNseq variant-calling technology into Qiagen's CLC Genomics Workbench and the Qiagen Clinical Insight platform.
The Personalized Medicine Coalition issued a report today highlight the recent advances in precision medicine as well as the remaining challenges.
A hospital study demonstrated an average total cost saving of around $25,000 for each patient with candidemia.
The Institute for Clinical and Economic Review is seeking public comment on its plan to evaluate the cost-effectiveness of EGFR inhibitors and immunotherapies.
Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.
John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.
Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.
In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.